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Abstract: Non-small cell lung cancer (NSCLC) represents about 85% of the reported cases of lung
cancer. Acquired resistance to targeted therapy with epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), such as gefitinib, is not uncommon. It is thus vital to explore novel strategies
to restore sensitivity to gefitinib. Provided that microRNAs (miRNAs) negatively regulate their gene
targets at the transcriptional level, it is speculated that miRNA mimetics may reduce the expression,
activity and signal transduction of EGFR so that sensitization of tumour sites to gefitinib-induced
cytotoxicity can be achieved. Indeed, a growing body of evidence has shown that the manipulation
of endogenous levels of miRNA not only attenuates the EGFR/PI3K/Akt phosphorylation cascade,
but also restores apoptotic cell death in in vitro models of experimentally-induced gefitinib resistance
and provoked tumour regression/shrinkage in xenograft models. These data are in concordant
with the clinical data showing that the differential expression profiles of miRNA in tumour tissues
and blood associate strongly with drug response and overall survival. Furthermore, another line of
studies indicate that the chemopreventive effects of a variety of natural compounds may involve
miRNAs. The present review aims to discuss the therapeutic capacity of miRNAs in relation to recent
discoveries on EGFR-TKI resistance, including chronic drug exposure and mutations.
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1. Introduction
Non-small cell lung cancer (NSCLC) makes up about 85% of the reported cases of lung cancer.
Approximately 10% of NSCLC patients manifest mutations of epidermal growth factor receptor
(EGFR), resulting in hyperactivation of downstream oncogenic pathways related to cell proliferation
and survival [1]; hence pointing out a therapeutic opportunity through the pharmacological blockade
of EGFR. Unfortunately, the emergence of resistance to targeted therapy with epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, has been found in a considerable
number of patients with repeated therapeutic cycles [2]. Currently, there is no effective approach
to reverse the mutations associated with drug resistance, and the inhibition of EGFR alone appears
to be insufficient to produce promising clinical outcomes. It is thus necessary to explore novel
pharmacological strategies to deactivate the EGFR signalling pathway at multiple levels.
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Mature microRNAs (miRNAs) are single-stranded, non-coding RNAs composed of
19–22 nucleotides which have tremendous impact on the transcriptome. Activation of miRNA involves
the “trimming” of a primary transcript consisting of hundreds of nucleotides through the action
of Drosha, which is a RNA-specific endonuclease, to premature pre-miRNA that is approximately
80 nucleotides in length. Furthermore, pre-miRNA is subject to modification by Dicer protein in the
cytoplasm as double-stranded miRNA, but only one of the strands would eventually incorporate with
the RNA-induced silencing complex (RISC). Provided that miRNAs induce transcriptional repression
through complementary pairing of the 31-untranslated region (UTR) with the transcripts of interest,
it is plausible to postulate that the introduction of miRNA mimetics may reduce the expression, activity
and signal transduction of EGFR such that the cytotoxicity of gefitinib can be restored in tumours
exhibiting impaired drug response [3]. This review aims to support efforts to improve the therapeutic
effects of miRNAs through the discussion of (1) the benefits and limitations of combined treatment
with gefitinib; (2) recent investigations of putative actions of miRNAs; and (3) potential synergistic
effects with natural compounds.
2. Overcoming Gefitinib Resistance: Not Only an Issue of EGFR
Reversible EGFR-TKIs, such as gefitinib and erlotinib, are considered the frontline treatment
for advanced NSCLC patients harbouring EGFR mutations. Unfortunately, the therapeutic efficacies
of EGFR-TKIs are known to be impeded by mutations of EGFRs. Activating mutations, such as
deletions in exon 19 and amino acid substitutions in exon 21 including the well-documented L858R
point mutation, elevate the intrinsic tyrosine kinase activity of EGFRs, an effect which establishes
the rationale of treatment with EGFR-TKI to reduce competitive binding of adenosine triphosphate
(ATP) [4]. Notably, these mutations have been clinically proven evident in NSCLC specimens of
gefitinib-responsive patients [1]. Insertions in exon 20 and T790M missense mutation, however,
are thought to be early genetic events which confer EGFR-TKI resistance in NSCLCs [5]. It is
thought that the threonine-to-methionine substitution at residue 790 would increase steric hindrance
at the ATP-binding pocket of EGFR, thereby preventing the binding of gefitinib while favouring the
docking of ATP [6]. Structural analyses have revealed that the ATP-binding domain was unaltered in
D770_N771insNPG subtype, which is one of the exon 20 insertion mutants exhibiting active kinase
activity [7]. Intriguingly, erlotinib mitigated the phosphorylation levels of EGFRThr1068, AktSer473 and
MAPKThr202 and augmented apoptotic cell death measured as Bim and cleaved PARP in BID007 cells
harbouring the A763_Y764insFQEA variant of exon 20 [7]. This observation is in line with the clinical
data that A763_Y764insFQEA-positive patients manifested drug response to erlotinib [7], although the
underlying mechanisms accounting for these conflicting findings are not known.
The phenomenon of EGFR-TKI resistance has called for intense efforts in search of novel,
alternative therapeutic opportunities. The fact that T790M mutation increases recruitment and
binding of ATP but not EGFR-TKIs and is found in 68% of NSCLC patients with defective responses
to EGFR-TKIs [8] have strived for the exploration of irreversible-EGFR-TKIs such as afatinib.
Nevertheless, given the role of EGFRs in the maintenance of skin and mucosal health, it is not
unexpected that irreversible inhibition of EGFR would be associated with more severe off-target effects.
It was reported that grade 3 rash and diarrhoea were prominent in patients exposed to afatinib therapy
compared to those treated with erlotinib (afatinib vs. erlotinib: rash: 28% vs. 13%; diarrhoea: 22%
vs. 5%) [9,10]. A recent retrospective analysis has reported that afatinib did not confer significant
benefits to T790M-positive patients, and the overall survival of these patients was found to diminish
further upon concomitant harbouring of exon 19 deletions compared with L858R mutations [11].
These results raise the need for the identification of molecular targets that would be of higher
therapeutic value. Targeting vascular endothelial growth factor (VEGF) by the monoclonal antibody
bevacizumab was observed to achieve 81%, 66% and 57% inhibition of tumour growth in H157, H460
and A549 xenografts respectively [12]. These data coincided with the amount of VEGF secretion in vitro
(H157 > H460 > A549), thereby suggesting that up-regulation of VEGF may represent a pathogenic
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mechanism that contributes to the resistance to EGFR-TKIs [12]. Phosphatidylinositol-3-kinase
(PI3K) and mammalian target of rapamycin (mTOR) are 2 upstream molecules known to activate the
protein kinase B (Akt) phosphorylation cascade. Simultaneous repression of the PI3K/mTOR axis by
NVP-BEZ235 was reported to ameliorate growth and migration of gefitinib-resistant H1975 cells and
induce tumour shrinkage in H1975-bearing mice [13]. It is also noteworthy that the immunoreactivities
of VEGF and cluster of differentiation 31 (CD31) were blunted concurrently in NVP-BEZ235-treated
H1975 tumours compared with the untreated counterparts [13]. Provided that H1975 is an in vitro
model of gefitinib resistance harbouring both L858R and T790M mutations, researching VEGF effectors
may have important translational implications in clinical oncology.
It has also been proposed recently that disruptions of mitochondrial function by oxidative stress
may modulate gefitinib resistance. Chronic exposure to gefitinib reduced mitochondrial number and
respiration and up-regulated remarkably vimentin, a marker indicative of drug resistance in H1650
cells whereas these alterations were reversed by mTempo, which is a free radical scavenger [14]. Under
aerobic conditions, pyruvate dehydrogenase (PDH) is essential for the conversion of pyruvate, which is
a glycolytic metabolite, into acetyl-CoA prior to the entry of the Kreb Cycle. Importantly, intracellular
production of reactive oxygen species (ROS) and protein expression of E1α/β and E3bp subunits of
PDH were elevated and attenuated respectively, in gefitinib-resistant H1650 clones relative to their
parental counterparts [14]. Although the linkage between increased oxidative stress and acquisition of
drug resistance is lacking, the data point to the notion that augmentation of mitochondrial function by
antioxidants may have preventive/therapeutic values in gefitinib-resistant NSCLCs.
3. Does Combination Treatment Enhance the Therapeutic Capacity of EGFR-TKIs?
Emerging evidence suggests that the anti-tumour activity of EGFR-TKIs in resistant NSCLC
cell lines can be enhanced by combined therapy with other regimens. Early efforts have shown that
cetuximab, which is an EGFR-targeting monoclonal antibody, produced synergistic anti-proliferative
effects in various tumour cell lines including H226 when used in combination with gefitinib or
erlotinib [15]. Further analyses with SCC-1, which is an in vitro model of head and neck tumour,
uncovered that apoptotic activation and repression of phosphorylated EGFR/Akt/MAPK were more
pronounced in the cetuximab plus gefitinib group compared with the gefitinib-treated group [15].
These data are in agreement with a recent attempt showingthat concomitant use of bevacizumab and
erlotinib reduced tumour growth remarkably by more than 85% in H157 xenografts relative to less
than 40% only in littermates treated with erlotinib alone [12]. Compared with PC9 and HCC827 cells
of which also possess deletion of exon 19, the reduction of phosphorylated EGFRThr1135 in H1650 was
not paralleled by elevated cleavages of caspase 3 and PARP in response to gefitinib treatment [16].
Simultaneous blockade of IGFR (insulin growth factor receptor) by AG1024, on the contrary, increased
the contents of cleaved caspase 3 and PARP and induced apoptotic cell death in H1650 cells [16].
These data are in support of a recent study exhibiting that gefitinib decreased tumour volumes in
H1975-implanted mice only when administered in combination with NVP-BEZ235, which is a dual
inhibitor of PI3K/mTOR [13].
Another conflicting line of evidence suggests that dual treatment may not necessarily followed by
synergistic therapeutic effects. While substantial growth delay and down-regulation of proliferating
cell nuclear antigen (PCNA) in H226 tumours were more evident in athymic mice subject to combined
therapy with cetuximab and gefitinib/erlotinib relative to their counterparts receiving single treatment
with either of the drugs studied [15], these results were not reproduced clinically. Co-administration
with cetuximab and erlotinib failed to elicit significant radiographic responses in metastatic lung
adenocarcinoma patients with T790M mutation, thus implying that alleviating EGFR activity by
current approaches may not be sufficient to confer significant treatment outcomes [17]. In a recent
study, suppression of A549 tumour growth by bebacizumab and erlotinib was not more effective than
that by erlotinib alone, which was attributable to the low expression of VEGF in the tumour tissues
concerned [12].
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4. Therapeutic Potential of MicroRNAs to Revert Gefitinib Competence
MicroRNAs (miRNAs) have gained increasingly attentions from researchers worldwide due to its
known transcriptional silencing effects by which may modulate multiple signalling cascades. While
the centre of attention of the current work is to review miRNA regulation in gefitinib-resistant NSCLC,
further readings are recommended for readers interested in the implications of miRNAs in other cancer
types [18] and recent attempts uncovering the roles of miRNAs in resistance mechanisms of commonly
prescribed chemotherapeutics in lung cancer [19]. Studies involving miRNA interventions to attenuate
EFGR-TKI resistant phenotypes are encouraging. Although most of them did not elucidate whether
the observable effects (augmentation of apoptosis, etc.) were due to direct degradation of the target
of study or secondary to the repression of other regulatory molecules, inactivation of EGFR/MET
appears to be a common mechanism of various miRNAs (Table 1).
Table 1. Recent studies on putative actions of various miRNAs.
miRNAs Models of EGFR-TKI Resistance Molecular Targets References
miR-34a 1. HGF/gefitinib-treated HCC8272. xenografts
Ò PARP cleavage
Ó p-MET/MET
Ó p-EGFR
[20]
miR-7 1. A549 Ó EGFR [21]
miR-146a 1. H1975 2. Human NSCLC
Ò Caspase 3/7 activity
Ó p-EGFR/EGFR
Ó p-Akt
[22]
miR-9-3 1. H1975 Ò Caspase 3 activityÒ DNA fragmentation [23]
miR-210 1. A549 Ó OXPHOSÒ HIF-1α [24]
miR-150 1. Human lung cancer samples2. A549/H1975 Ó SRCIN1 [25]
miR-21 1. PC9 xenografts 2. HumanNSCLC samples Ò p-Akt/Akt [26]
miR-101 1. H157 ? ATM [27]
miR-Let-7c
1. H441 Ó p-STAT3 [28]
2. H1975 Ó Ras/p-Akt [29]
EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; Ò, induction; Ó, repression;
?, unknown effect.
Restoration of gefitinib sensitivity has been observed in different NSCLC cell lines with
chronic gefitinib exposure in response to miRNA stimulation. It has been reported recently that
miR-34a reversed gefitinib resistance in HCC827 cells induced by concomitant incubation with
hepatocyte growth factor (HGF) and gefitinib [20]. This concept is well-supported by the data
showing that miR-34a restored apoptosis measured as percentage of apoptotic cells and cleaved
PARP and reduced the protein abundances of both total and phosphorylated MET [20]. Consistent
findings in vivo revealed that miR-34a induced regression of gefitinib-resistant tumours in conjunction
with gefitinib intervention, an effect that could be ascribed to reduced expression of MET and
phospho-EGFRTyr1068 [20]. Although gene amplification of MET is only reported in 11% of the
NSCLC patients [8], inhibition of MET by miR-34a may present a promising curative solution for
these patients. Microarray analyses have identified that chronic gefitinib exposure increased the
expression of 25 miRNAs while repressed 18 others in A549 clones; this differential expression profile
was associated with a 3-fold increase in IC50 of gefitinib [21]. In line with the finding that miR-7 showed
the most remarkable change in expression (i.e., a 14-fold reduction) among other miRNA members
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studied, transfection with miR-7 abolished the elevation of EGFR and restored drug sensitivity in A549
cells exposed to long-term escalating doses of gefitinib [21].
The pro-apoptotic capacity of miRNAs has also been supported by data obtained from
experimental models of acquired gefitinib resistance. Transfection with miR-138-5p mimics induced
a dramatic sensitizing response to gefitinib in H1975 cells, which is in line with the observation
that 6-month gefitinib exposure reduced miR-138-5p expression by 10 folds [30]. Incubation with
miR-146a mimic elevated the number of apoptotic nuclei measured by PI fluorescent staining and
activity of caspase 3/7 while mitigated phosphorylations of EGFRTyr1173 and AktSer473 in H1975 cells,
despite the fact that these effects were less pronounced relative to those induced by EGFR-targeting
small-interfering RNA (siRNA) [22]. It is noteworthy that the total protein content of EGFR was
concurrently reduced in response to miR-146a treatment, thus implying that EFGR is a modulating
target of miR-146a [22]. Furthermore, the expression of miR-146a was ~63% lower in NSCLC samples
compared with normal lung tissues whereas low expression of miR-146a was evident in patients
with stage III/IV NSCLCs, thus pointing to the clinical significance of miR-146a in the progression
of NSCLCs [22]. Recent evidence also showed that miR-146a induced direct repression on insulin
receptor substrate 2 (IRS2), an adaptor protein essential in cell metabolism, at both transcript and
protein levels [31]. Taken into consideration the fact that miR-146a expression was impaired in
advanced lung cancer samples, strategies that inactivate metabolic/apoptotic signalling through
the augmentation of endogenous level of miR-146a may re-sensitize patients to gefitinib therapy.
Corroborating with the observation that the expression of miR-200c was reduced in clinical lung cancer
specimens, the percentage of apoptotic cells was increased after over-expression of miR-200c in H460
cells [32]. These results imply that the capacity of miRNAs to manipulate the apoptotic pathway may
provide high translational value to re-establish the therapeutic efficacy of EGFR-TKIs such as gefitinib.
The functional role of miRNAs in gefitinib resistance has also been characterized by epigenetic
approaches. Experiments involving methylation-specific PCR analyses have demonstrated that
the promoter of miR-9-3 was hypermethylated in H1975 cells [23]. Demethylation of miR-9-3 by
5-Aza-21-deoxycytidine enhanced apoptosis measured as DNA fragmentation and caspase 3 activity
induced by doxorubicin, which is a common prescription for breast cancer; these demethylation-related
effects were antagonized by anti-miR-9-3 oligomer [23]. Previous efforts also indicated that the protein
contents of Fas and anti-apoptotic Bcl2 were elevated and reduced respectively in H157 tumours
expressing siRNA specific to the complement inhibiting protein CD59 [33], although whether the
changes involved epigenetic regulation were unknown. Importantly, knocking down of CD59 in
tumour bearing mice led to a survival rate of 70% compared with 0% in the counterparts with
undisrupted CD59 expression [33]. The aforementioned findings therefore suggest that transcriptional
repression by miRNAs may present a novel and effective therapeutic opportunity to NSCLC patients
with EGFR-TKI resistance through the restoration of apoptosis as with direct target inhibition
by siRNAs.
5. The Need of Clear, Functional Dissection of miRNAs
A growing body of opposing data suggests that not every miRNA would induce sensitizing
drug response. Over-expression of miR-210 attenuated the expression of genes related to oxidative
phosphorylation and induced enlargement of the mitochondria; these observations were coincident
with the stabilization of hypoxia-inducing factor 1 alpha (HIF-1α) in A549 cells [24]. Further
efforts elucidated that the increased stability of HIF-1α protein was followed by enhanced survival,
although the p53 apoptotic pathway measured as p53, p21 and cleaved caspase 3 was activated with
escalating dose of radiation [24]. Interestingly, the level of miR-150 was elevated in concomitant
with reduction of SRCIN1 protein, which is an inhibitor of Src, in human lung cancer samples [25].
This inverse correlation was found to determine the migration capacity in vitro: transfection with
miR-150 potentiated while forced expression of SRCIN1 alleviated cell migration [25]. In accordance
with the observation that patients with high expression of miR-21 in NSCLC tissues manifested poor
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drug response and shortened overall survival, transcriptional silencing of miR-21 reduced tumour
volume in mice implanted with gefitinib-resistant PC9 whereas forced-expression of miR-21 in vitro
enhanced phosphorylation of AktSer473 and cell viability [26]. The notion that miR-21 mediates gefitinib
resistance was confirmed further by the study demonstrating that intra-tumour administration with
anti-miR-21 oligonucleotides antagonized the elevation of Akt in both total and phosphorylated
forms in gefitinib-resistant PC9 tumours [34]. Experiments with H69AR, a cell line of small cell
lung cancer, showed that miR-134, miR-379 and miR-495 were pivotal to the sensitizing response
to various chemotherapeutics including cisplatin and doxorubicin, although whether perturbations
of the miRNAs concerned would account for gefitinib resistance in NSCLC should merit further
investigation [35]. In addition, it is also thought that the therapeutic efficacy of exogenous miRNAs
would be confined by their intrinsic levels in vitro. A representative example of the claim would be
that further stimulation with miR-101 in H157, a NSCLC cell line in which the expression of miR-101
is remarkably high, was not accompanied by reductions in surviving fraction and protein content of
ATM (a target of miR-101 known to be involved in DNA repair) in response to ionizing radiation [27].
Similar results were replicated in in vivo: miR-101 blunted the growth of A549 and H1975 xenografts
whereas the size of H157 tumours did not differ significantly with ectopic expression of miR-101 [27].
Intriguingly, miR-30c and miR-221/222 were robustly down-regulated after transcriptional inactivation
of EFFR/MET in Calu1 cells, which is a gefitinib-unreceptive NSCLC cell line [36]. Subsequent analyses
have demonstrated that these effects were only mimicked in gefitinib-sensitive PC9, but neither in
Calu1 nor A549 after gefitinib incubation, therefore leading to the speculation that miR-30c and
miR-221/222 may appear to be attractive intervention targets to reverse gefitinib resistance. However,
it is not known how these miRNAs were regulated by EGFR and whether any synergism/antagonism
exists among the miRNAs studied [36].
A growing body of evidence has proposed the use of miRNAs as markers of diagnosis and
prognosis. In NSCLC patients, the expression of miR-21 in the serum was elevated and more
importantly, patients with higher circulating levels of miR-21 had shorter survival time compared with
those with lower levels [37]. This observation concurs with the inverse correlation between miR-21
expression in lung cancer tissues and response to gefitinib treatment [26]. Comparison among NSCLC
patients has identified that the expression of miR-1260b was elevated by 2.7 folds in individuals with
confirmed metastasis [38], suggesting that miR-1260b may modulate markers associated with the
invasion process such as E-cadherin and vimentin as those reported with miR-520h [39]. Knocking
down of miR-1620b consistently decreased migration activity of prostate cancer cells, an effect that
could be at least in part, attributed to the negative regulation of Smad4 by miR-1620b, although
whether this would also be a missing opportunity to regain sensitivity in gefitinib-resistant patients
remains unknown [40]. A recent attempt has demonstrated the reliability of a miRNA signature
consisting of miR-483-5p, miR-193a-3p, miR-25, miR-214 and miR-7, to characterize NSCLC patients
in ethnically-diverse populations with success [41]. Notably, miR-7 was found to be elevated
approximately 2-fold in sera from NSCLC patients compared to the control counterparts [41], which
is contradictory to the observation that over-expression of miR-7 suppressed EGFR and induced
sensitizing response to gefitinib in vitro [21]. In agreement with the observation that administration of
miR-200c extended the survival of mice inoculated with H460, which is a NSCLC cell line known to
express wild-type EGFR [32], the expression level of miR-200c was positively correlated with beneficial
clinical outcome in advanced NSCLC patients receiving gefitinib/erlotinib therapies with no known
EGFR mutations [42]. It is worth-noting, however, that this association was not found in NSCLC
patients habouring EGFR mutations, despite the fact that a similar trend was observed [42], thus
implying that the modes of action of miR-200c may be apparently distinct between conditions that are
receptive/reluctant to gefitinib-induced cytotoxicity. It is certain that more research is necessary to
determine the mechanisms underlying these inconsistent findings.
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6. Synergy with Natural Phytochemicals
Emerging evidence also suggests that miRNAs may mediate the chemopreventive effects
of natural, dietary compounds (Table 2) and thus may account for the reported changes in the
epigenetic machineries and canonical PI3K/Akt survival signalling pathway as reviewed extensively
elsewhere [43].
Table 2. Modulation of miRNAs by natural compounds.
Compounds
of Interest Changes in miRNA Signalling Markers Involved References
Antrocin Ò miR-Let-7c Ó Akt, JAK1/2, STAT3Ò Bax, cleavage of caspase 3 [28]
Resveratrol
Ò miR-335
Ò miR-582-3p
Ò miR-338-3p
Ò miR194 and more
A number of genes related to
apoptosis, cell cycle arrest and
proliferation (Predicted)
[44]
Ò miR-622 Ó k-Ras [45]
Augments the effects of
miR-200c Ò caspase 3/9, CHOP, p-JNK [32]
? miR-21 Ò Bcl2 [46]
Ó miR-520h Ò PP2A, E-cadherinÓ p-Akt, FOXC2, vimentin [39]
Curcumin
Ò miR-192-5p, miR-215 Ò p53, p21 [47]
Ó miR-186 Ò caspase 10 [48]
Antrocin is one of the most abundant small molecules of medicinal mushroom believed to
confer preventive effects against the development of cancer. Recent attempts have demonstrated
that antrocin mitigated phosphorylations of various survival-related kinases including AktSer473,
JAK1/2Tyr1002/Tyr1007 and STAT3Tyr705 and stimulated apoptosis indicated by increased expression
of pro-apoptotic Bax and cleavage of caspase 3 and down-regulation of anti-apoptotic Bcl2 in H441
cells [28]. What is of higher importance is that all these observations coincided with an elevated
abundance of miR-Let-7c, suggesting that miR-Let-7c might promote cell death in NSCLCs [28].
This postulation is confirmed by the experiments showing that transient induction of miR-Let-7c
ameliorated the activity of STAT3 and formation of colonies, in which all these effects were amplified
by combination treatment with antrocin [28]. Compelling data also documented that forced expression
of miR-Let-7c in H1975 cells restored the cytotoxicity of gefitinib, an effect observed concomitantly with
decreases in protein contents of oncogenic Ras and phosphorylated AktSer473 [29]. Recent attempts to
enhance the effect of erlotinib with combinations of miR-Let-7c and miR-34 were of a great success [49].
Extrapolation of the aforementioned findings to natural phytochemicals is apparently an important
scope of research, provided that the concepts of off-target symptoms of erlotinib and association
between miR-Let-7c and shortened survival in lung cancer patients are well-established [50].
Previous efforts have also shown that resveratrol, which is a natural antioxidant in grapes and
red wine, modulated an array of miRNAs in A549 cells. In particular, the expression of various
miRNA members changed abruptly with resveratrol stimulation (miR-335: 19.87-fold; miR-582-3p:
21.4-fold; miR-338-3p: 36.59-fold; miR194: 42.91-fold, etc.) [44]. Using bioinformatics analysis, a panel
of genes related to apoptosis, cell-cycle arrest, growth and proliferation were predicted to be targets of
the aforementioned miRNAs [44]. MicroRNA profiling analyses have indicated that the content of
miR-622 was robustly elevated by resveratrol incubation in cultures of H460 and 16HBE-T, which is a
transformed form of the bronchial epithelial cell line 16HBE [45]. In concordance with the diminished
viability in resveratrol-treated 16HBE-T cells, increased cell cycle arrest and blunted proliferation were
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observed in both cell lines with transient up-regulation of miR-622 [45]. It is also noteworthy that
resveratrol did not perturb the viability of normal epithelial cells and mice transfected with miR-622
manifested lighter tumours upon challenge with 16HBE-T inoculation, hence bringing forward the
possibility that the manipulation of miR-622 by resveratrol may elicit specific therapeutic outcomes
in lung cancer patients with minimal undesired effects [45]. Given that transcriptional repression
of Bcl2 was provoked secondary to the resveratrol-induced decrease in miR-21expression in in vitro
models of pancreatic cancer [46] whereas miR-21 has been reported to be associated with poor drug
treatment outcomes in lung cancer patients [26], it is tempting to investigate whether the miR-21/Bcl2
axis would represent a mechanism of action of resveratrol in the combat against drug resistance in
NSCLC. Recent attempts have proposed a critical role formiR-520h during lung cancer metastasis,
by which its over-expression antagonized the stimulation of PP2A by resveratrol, leading to the
reversion of a high phosphorylation level of Akt and ultimately, the migrating capacity of A549
cells [39]. All these studies support the speculation that pharmacological activation/inactivation of
endogenous, clinically-relevant miRNAs by resveratrol may revert the sensitivity of lung cancer tissues
to gefitinib therapy.
Curcumin, a bioactive ingredient in curry, has been demonstrated to elevate significantly the
contents of miR-192-5p and miR-215 concomitantly with pro-apoptotic p53 and cell-arresting p21
in H460 cells [47]. Experiments with A549 cells unraveled that curcumin up-regulated caspase 10
robustly and repressed proliferation whereas these findings were recapitulated with the inhibition of
miR-186 [48]. Of note, similar findings were observed with forced expression of a miR-186 inhibitor in
A549/DDP multidrug-resistant human lung adenocarcinoma cells, thereby confirming the oncogenic
nature of miR-186 [51]. Transfection with miR-21 mimic in A549 cells was found to abrogate the
anti-proliferative/anti-apoptotic effects of curcumin as determined by MTT assay and annexin-V/PI
staining respectively [52]. Corroborating data obtained from pancreatic cancer cells have also revealed
that resveratrol increased the transcript contents of various tumour suppressors known to be regulated
negatively by miR-21 [53]. Taken into consideration the fact that the negative correlation between
miR-21 expression and relapse-free survival in NSCLC patients is well-documented [54], these studies
provide an important insight that pharmacological blockade of miR-21 by curcumin/resveratrol may
improve the prognosis with gefitinib treatment. Activation of caspase 3 and PARP fragmentation,
which are markers indicative of apoptosis, were observed in A549 cells following over-expression
of miR-192-5p and miR-215 whereas these findings were reproduced with curcumin incubation [47].
Furthermore, the induction of miR-192-5p and miR-215 by curcumin required the presence of functional
p53 protein, hence leading to the thought that the anti-tumour effects of curcumin and its miRNA
targets may orchestrate through a positive-feedback manner [47].
Nevertheless, it remains largely unknown whether the therapeutic values of these natural
compounds would be augmented by simultaneous treatment with their putative miRNA mimetics.
An encouraging study has shown that combined injection of resveratrol and miR-200c prolonged the
survival of H460-bearing mice more remarkably than either treatment alone; by which this effect could
be in part ascribed to the increases in caspase 3, caspase 9 and CHOP [32]. Taken together, these studies
shall empower future research to dissect the synergistic/antagonistic mechanisms between miRNAs
and natural compounds to remedy gefitinib-resistant NSCLCs, a clinically-significant challenge in
lung cancer.
7. Conclusions
Whilst overcoming the mutations causing gefitinib resistance in NSCLC patients are apparently
infeasible at the present moment, researching molecules associated with proliferation, survival and
cell death offers an alternate approach for biomarker discovery and the development of novel
therapeutic regimens. A growing body of data points out that various miRNAs impede the growth
of gefitinib-resistant tumours both in vitro and in vivo, meaning these effects can be attributed largely
to the manipulation of EGFR/MET pathway and apoptotic cell death (Figure 1). Recent studies also
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suggest that the chemopreventive effects of various natural dietary compounds may involve the
modulation of miRNAs. Nevertheless, whether combined therapy with phytochemicals and miRNAs
would provoke more pronounced anti-cancer effects warrants further investigation.
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Figure 1. Plausible mechanisms of action of miRNAs in the restoration of gefitinib sensitivity. 
Incompetent repression of epidermal growth factor receptor (EGFR) is a molecular hallmark of 
gefitinib resistance. Hence, targeting signalling markers downstream of EGFR may provide novel 
therapeutic opportunity for NSCLC patients with acquired gefitinib resistance. Intense research 
efforts have demonstrated the capacity of miRNAs in the modulation of a number of signalling 
molecules related to growth/proliferation (Ras and SRCIN), apoptotic cell death/cell cycle arrest (p53, 
Bax, caspases and p21) and cell invasion (E-cadherin and vimentin) in conjunction with the EGFR 
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Figure 1. Plausible mechanisms of action of miRNAs in the restoration of gefitinib sensitivity.
Incompetent repression of epidermal growth factor receptor (EGFR) is a molecular hallmark of gefitinib
resistance. Hence, targeting signalling markers downstream of EGFR may provide novel therapeutic
opportunity for NSCLC patients with acquired gefitinib resistance. Intense research efforts have
demonstrated the capacity of miRNAs in the modulation of a number of signalling molecules related
to growth/proliferation (Ras and SRCIN), apoptotic cell death/cell cycle arrest (p53, Bax, caspases
and p21) and cell invasion (E-cadherin and vimentin) in conjunction with the EGFR phosphorylation
cascade (Akt), which may contribute to the reversion of gefitinib sensitivity. Blue arrow, stimulation;
red “T” sign, inhibition; dashed arrows, indication of cellular components.
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